Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 1
1979 1
1981 1
1982 1
1983 1
1984 1
1985 1
1987 1
1988 1
1990 3
1991 1
1992 3
1993 6
1994 6
1995 6
1996 2
1997 6
1998 4
1999 6
2000 2
2001 10
2002 10
2003 16
2004 12
2005 9
2006 7
2007 18
2008 9
2009 17
2010 11
2011 14
2012 17
2013 20
2014 15
2015 19
2016 19
2017 21
2018 18
2019 18
2020 28
2021 43
2022 51
2023 41
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

450 results

Results by year

Filters applied: . Clear all
Page 1
Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, D'Amico TA, DeCamp M, Dilling TJ, Dowell J, Gettinger S, Grotz TE, Gubens MA, Hegde A, Lackner RP, Lanuti M, Lin J, Loo BW, Lovly CM, Maldonado F, Massarelli E, Morgensztern D, Ng T, Otterson GA, Pacheco JM, Patel SP, Riely GJ, Riess J, Schild SE, Shapiro TA, Singh AP, Stevenson J, Tam A, Tanvetyanon T, Yanagawa J, Yang SC, Yau E, Gregory K, Hughes M. Ettinger DS, et al. J Natl Compr Canc Netw. 2022 May;20(5):497-530. doi: 10.6004/jnccn.2022.0025. J Natl Compr Canc Netw. 2022. PMID: 35545176
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non-Small Cell Lung Cancer (NSCLC) provide recommended management for patients with NSCLC, including diagnosis, primary treatment, surveillance for relapse, and subsequent treatment. P …
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non-Small Cell Lung Cancer (NSCLC) provide r …
Non-small cell lung cancer (NSCLC): A review of risk factors, diagnosis, and treatment.
Alduais Y, Zhang H, Fan F, Chen J, Chen B. Alduais Y, et al. Medicine (Baltimore). 2023 Feb 22;102(8):e32899. doi: 10.1097/MD.0000000000032899. Medicine (Baltimore). 2023. PMID: 36827002 Free article. Review.
Lung cancer remains the leading cause of cancer deaths. Non-small cell lung cancer (NSCLC) is the most frequent subtype of lung cancer. Surgery, radiation, chemotherapy, immunotherapy, or molecularly targeted therapy is used to tre …
Lung cancer remains the leading cause of cancer deaths. Non-small cell lung cancer (NSCLC) is the most fr …
Extensive-Stage Small-Cell Lung Cancer: First-Line and Second-Line Treatment Options.
Zugazagoitia J, Paz-Ares L. Zugazagoitia J, et al. J Clin Oncol. 2022 Feb 20;40(6):671-680. doi: 10.1200/JCO.21.01881. Epub 2022 Jan 5. J Clin Oncol. 2022. PMID: 34985925 Review.
Extensive-stage small-cell lung cancer is a therapeutically challenging disease. ...Although newer treatments are being incorporated in the relapse setting, marked therapeutic resistance is typically observed in patients with relapsed small …
Extensive-stage small-cell lung cancer is a therapeutically challenging disease. ...Although newer treatments ar …
Management of Stage III Non-Small-Cell Lung Cancer: ASCO Guideline.
Daly ME, Singh N, Ismaila N, Antonoff MB, Arenberg DA, Bradley J, David E, Detterbeck F, Früh M, Gubens MA, Moore AC, Padda SK, Patel JD, Phillips T, Qin A, Robinson C, Simone CB 2nd. Daly ME, et al. J Clin Oncol. 2022 Apr 20;40(12):1356-1384. doi: 10.1200/JCO.21.02528. Epub 2021 Dec 22. J Clin Oncol. 2022. PMID: 34936470 Review.
PURPOSE: To provide evidence-based recommendations to practicing clinicians on management of patients with stage III non-small-cell lung cancer (NSCLC). METHODS: An Expert Panel of medical oncology, thoracic surgery, radiation oncology, pulmonary oncol …
PURPOSE: To provide evidence-based recommendations to practicing clinicians on management of patients with stage III non-small …
Early stage NSCLC - challenges to implementing ctDNA-based screening and MRD detection.
Abbosh C, Birkbak NJ, Swanton C. Abbosh C, et al. Nat Rev Clin Oncol. 2018 Sep;15(9):577-586. doi: 10.1038/s41571-018-0058-3. Nat Rev Clin Oncol. 2018. PMID: 29968853 Review.
Advances in DNA sequencing technologies and our understanding of the molecular biology of tumours have resulted in increased interest in exploiting ctDNA as a tool to facilitate earlier detection of cancer and thereby improve therapeutic outcomes by enabling early interven …
Advances in DNA sequencing technologies and our understanding of the molecular biology of tumours have resulted in increased interest in exp …
Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer.
Gale D, Heider K, Ruiz-Valdepenas A, Hackinger S, Perry M, Marsico G, Rundell V, Wulff J, Sharma G, Knock H, Castedo J, Cooper W, Zhao H, Smith CG, Garg S, Anand S, Howarth K, Gilligan D, Harden SV, Rassl DM, Rintoul RC, Rosenfeld N. Gale D, et al. Ann Oncol. 2022 May;33(5):500-510. doi: 10.1016/j.annonc.2022.02.007. Epub 2022 Mar 17. Ann Oncol. 2022. PMID: 35306155 Free PMC article.
BACKGROUND: Identification of residual disease in patients with localized non-small cell lung cancer (NSCLC) following treatment with curative intent holds promise to identify patients at risk of relapse. ...Detection before treatment was associated wi …
BACKGROUND: Identification of residual disease in patients with localized non-small cell lung cancer (NSCLC) fol …
Potential clinical utility of liquid biopsy in early-stage non-small cell lung cancer.
Shen H, Jin Y, Zhao H, Wu M, Zhang K, Wei Z, Wang X, Wang Z, Li Y, Yang F, Wang J, Chen K. Shen H, et al. BMC Med. 2022 Dec 14;20(1):480. doi: 10.1186/s12916-022-02681-x. BMC Med. 2022. PMID: 36514063 Free PMC article.
BACKGROUND: Liquid biopsy has been widely researched for early diagnosis, prognostication and disease monitoring in lung cancer, but there is a need to investigate its clinical utility for early-stage non-small cell lung cancer (NSCLC). ...Hazar …
BACKGROUND: Liquid biopsy has been widely researched for early diagnosis, prognostication and disease monitoring in lung cancer, but …
Current treatment strategies for EGFR-mutated non-small cell lung cancer: from first line to beyond osimertinib resistance.
Araki T, Kanda S, Horinouchi H, Ohe Y. Araki T, et al. Jpn J Clin Oncol. 2023 Jun 29;53(7):547-561. doi: 10.1093/jjco/hyad052. Jpn J Clin Oncol. 2023. PMID: 37279591 Free PMC article. Review.
Osimertinib, a third-generation EGFR TKI, is the standard therapy for previously untreated EGFR-mutated non-small cell lung cancer patients following the landmark FLAURA study. ...This review describes current pharmacotherapeutic strategies for …
Osimertinib, a third-generation EGFR TKI, is the standard therapy for previously untreated EGFR-mutated non-small ce …
Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology.
Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman J, Chirieac LR, D'Amico TA, DeCamp MM, Dilling TJ, Dobelbower M, Doebele RC, Govindan R, Gubens MA, Hennon M, Horn L, Komaki R, Lackner RP, Lanuti M, Leal TA, Leisch LJ, Lilenbaum R, Lin J, Loo BW Jr, Martins R, Otterson GA, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Stevenson J, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M. Ettinger DS, et al. J Natl Compr Canc Netw. 2017 Apr;15(4):504-535. doi: 10.6004/jnccn.2017.0050. J Natl Compr Canc Netw. 2017. PMID: 28404761
This selection from the NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC) focuses on targeted therapies and immunotherapies for metastatic NSCLC, because therapeutic recommendations are rapidly changing for metastatic disease. ...
This selection from the NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC) focuses on targeted therapies …
Treatment of Oligometastatic Non-Small Cell Lung Cancer: An ASTRO/ESTRO Clinical Practice Guideline.
Iyengar P, All S, Berry MF, Boike TP, Bradfield L, Dingemans AC, Feldman J, Gomez DR, Hesketh PJ, Jabbour SK, Jeter M, Josipovic M, Lievens Y, McDonald F, Perez BA, Ricardi U, Ruffini E, De Ruysscher D, Saeed H, Schneider BJ, Senan S, Widder J, Guckenberger M. Iyengar P, et al. Pract Radiat Oncol. 2023 Sep-Oct;13(5):393-412. doi: 10.1016/j.prro.2023.04.004. Epub 2023 Apr 25. Pract Radiat Oncol. 2023. PMID: 37294262
PURPOSE: This joint guideline by American Society for Radiation Oncology (ASTRO) and the European Society for Radiotherapy and Oncology (ESTRO) was initiated to review evidence and provide recommendations regarding the use of local therapy in the management of extracranial …
PURPOSE: This joint guideline by American Society for Radiation Oncology (ASTRO) and the European Society for Radiotherapy and Oncology (EST …
450 results